Jeremy W Bray1, Brandon Aden2, Ashley A Eggman3, Leah Hellerstein4, Eve Wittenberg5, Bohdan Nosyk6, Judy C Stribling7, Bruce R Schackman8. 1. Department of Economics, The University of North Carolina at Greensboro, PO Box 26170, Greensboro, NC 27402, United States. Electronic address: jwbray@uncg.edu. 2. Department of Medicine, Weill Cornell Medical College, 409 E 60th Street, New York, NY 10022, United States; Department of Healthcare Policy & Research, Weill Cornell Medical College, 425 E 61st Street, New York, NY 10065, United States. Electronic address: bra2002@med.cornell.edu. 3. Department of Healthcare Policy & Research, Weill Cornell Medical College, 425 E 61st Street, New York, NY 10065, United States. Electronic address: eggerash@gmail.com. 4. Department of Healthcare Policy & Research, Weill Cornell Medical College, 425 E 61st Street, New York, NY 10065, United States. Electronic address: lhh45@cornell.edu. 5. Center for Health Decision Science, Harvard T.H. Chan School of Public Health, 718 Huntington Avenue, Boston, MA 02115, United States. Electronic address: ewittenb@hsph.harvard.edu. 6. British Columbia Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, B.C. V6Z 1Y6, Canada; Faculty of Health Sciences, Simon Fraser University, 8888 University Drive, Burnaby, B.C. V5A 1S6, Canada. Electronic address: bohdan_nosyk@sfu.ca. 7. Samuel J. Wood Library, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, United States. Electronic address: jcs2002@med.cornell.edu. 8. Department of Medicine, Weill Cornell Medical College, 409 E 60th Street, New York, NY 10022, United States; Department of Healthcare Policy & Research, Weill Cornell Medical College, 425 E 61st Street, New York, NY 10065, United States. Electronic address: brs2006@med.cornell.edu.
Abstract
BACKGROUND AND AIMS: The recent opioid epidemic has prompted renewed interest in opioid use disorder treatment, but there is little evidence regarding health-related quality-of-life (HRQoL) outcomes in treatment programs. Measuring HRQoL represents an opportunity to consider outcomes of opioid use disorder treatment that are more patient-centered and more relevant to overall health than abstinence alone. We conducted a systematic literature review to explore the extent to which the collection of HRQoL by opioid treatment programs is documented in the treatment program literature. MATERIALS AND METHODS: We searched PubMed, Embase PsycINFO and Web of Science for papers published between 1965 and 2015 that reported HRQoL outcome measures from substance abuse treatment programs. RESULTS: Of the 3014 unduplicated articles initially identified for screening, 99 articles met criteria for further review. Of those articles, 7 were unavailable in English; therefore 92 articles were reviewed. Of these articles, 44 included any quality-of-life measure, 17 of which included validated HRQoL measures, and 10 supported derivation of quality-adjusted life year utility weights. The most frequently used validated measure was the Addiction Severity Index (ASI). Non-U.S. and more recent studies were more likely to include a measure of HRQoL. CONCLUSIONS: HRQoL measures are rarely used as outcomes in opioid treatment programs. The field should incorporate HRQoL measures as standard practice, especially measures that can be used to derive utility weights, such as the SF-12 or EQ-5D. These instruments provide policy makers with evidence on the impact of programs on patients' lives and with data to quantify the value of investing in opioid use disorder treatments.
BACKGROUND AND AIMS: The recent opioid epidemic has prompted renewed interest in opioid use disorder treatment, but there is little evidence regarding health-related quality-of-life (HRQoL) outcomes in treatment programs. Measuring HRQoL represents an opportunity to consider outcomes of opioid use disorder treatment that are more patient-centered and more relevant to overall health than abstinence alone. We conducted a systematic literature review to explore the extent to which the collection of HRQoL by opioid treatment programs is documented in the treatment program literature. MATERIALS AND METHODS: We searched PubMed, Embase PsycINFO and Web of Science for papers published between 1965 and 2015 that reported HRQoL outcome measures from substance abuse treatment programs. RESULTS: Of the 3014 unduplicated articles initially identified for screening, 99 articles met criteria for further review. Of those articles, 7 were unavailable in English; therefore 92 articles were reviewed. Of these articles, 44 included any quality-of-life measure, 17 of which included validated HRQoL measures, and 10 supported derivation of quality-adjusted life year utility weights. The most frequently used validated measure was the Addiction Severity Index (ASI). Non-U.S. and more recent studies were more likely to include a measure of HRQoL. CONCLUSIONS: HRQoL measures are rarely used as outcomes in opioid treatment programs. The field should incorporate HRQoL measures as standard practice, especially measures that can be used to derive utility weights, such as the SF-12 or EQ-5D. These instruments provide policy makers with evidence on the impact of programs on patients' lives and with data to quantify the value of investing in opioid use disorder treatments.
Authors: Hans-Ulrich Wittchen; Sabine M Apelt; Michael Soyka; Markus Gastpar; Markus Backmund; Jörg Gölz; Michael R Kraus; Felix Tretter; Martin Schäfer; Jens Siegert; Norbert Scherbaum; Jürgen Rehm; Gerhard Bühringer Journal: Drug Alcohol Depend Date: 2008-03-11 Impact factor: 4.492
Authors: Daniel Polsky; Henry A Glick; Jianing Yang; Geetha A Subramaniam; Sabrina A Poole; George E Woody Journal: Addiction Date: 2010-07-12 Impact factor: 6.526
Authors: Bohdan Nosyk; Huiyung Sun; Daphne P Guh; Eugenia Oviedo-Joekes; David C Marsh; Suzanne Brissette; Martin T Schechter; Aslam H Anis Journal: J Clin Epidemiol Date: 2010-03-17 Impact factor: 6.437
Authors: Theresa W Kim; Jeffrey H Samet; Debbie M Cheng; Michael R Winter; Dana Gelb Safran; Richard Saitz Journal: Health Serv Res Date: 2007-04 Impact factor: 3.402
Authors: Sean M Murphy; Kathryn E McCollister; Jared A Leff; Xuan Yang; Philip J Jeng; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman Journal: Ann Intern Med Date: 2018-12-18 Impact factor: 25.391
Authors: Laura C Fanucchi; Sean M Murphy; Hilary Surratt; Shashi N Kapadia; Sharon L Walsh; James A Grubbs; Alice C Thornton; Paul Nuzzo; Michelle R Lofwall Journal: Ther Adv Infect Dis Date: 2022-07-11
Authors: Sunggeun Ethan Park; Jennifer E Mosley; Colleen M Grogan; Harold A Pollack; Keith Humphreys; Thomas D'Aunno; Peter D Friedmann Journal: J Subst Abuse Treat Date: 2020-09-03
Authors: Ali Jalali; Danielle A Ryan; Philip J Jeng; Kathryn E McCollister; Jared A Leff; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman; Sean M Murphy Journal: Drug Alcohol Depend Date: 2020-08-05 Impact factor: 4.492
Authors: Arthur Robin Williams; Edward V Nunes; Adam Bisaga; Harold A Pincus; Kimberly A Johnson; Aimee N Campbell; Remien H Remien; Stephen Crystal; Peter D Friedmann; Frances R Levin; Mark Olfson Journal: J Subst Abuse Treat Date: 2018-06-02
Authors: Jessica J Wyse; Benjamin J Morasco; Jacob Dougherty; Beau Edwards; Devan Kansagara; Adam J Gordon; P Todd Korthuis; Anaïs Tuepker; Stephan Lindner; Katherine Mackey; Beth Williams; Anders Herreid-O'Neill; Robin Paynter; Travis I Lovejoy Journal: Drug Alcohol Depend Date: 2021-07-29 Impact factor: 4.852